NIH Weekly Funding Opportunities and Policy Notices

Thursday, October 28, 2021 - 2:43am
Notice NOT-AG-21-064 from the NIH Guide for Grants and Contracts
Thursday, October 28, 2021 - 2:38am
Notice NOT-AG-21-054 from the NIH Guide for Grants and Contracts
Wednesday, October 27, 2021 - 1:06am
Funding Opportunity RFA-RM-22-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) within the Cellular Senescence Network (SenNet) to build an atlas of cellular senescence in mice. The overarching goal of the SenNet consortium is to identify and functionally characterize, at single-cell resolution, the heterogeneity of senescent cells across multiple human tissues in health and lifespan. A previous FOA (RFA-RM-21-008) established the TMCs to generate data and build maps in humans. The purpose of this FOA is to solicit applications that complement the human effort by generating an atlas of cell senescence in mice that will help inform the ongoing effort in humans and serve as a blueprint for future translational research performed in mice. Through collaborative efforts, the murine component of the consortium will generate a multimodal, multidimensional atlas of senescent cells in various murine tissues (tissue choices will be predominantly dictated by the corresponding human tissues already in use within the SenNet consortium); develop innovative tools and technologies to identify and characterize senescent cells; and aggregate data across the Network into a searchable atlas of murine Cellular Senescence. The TMCs solicited through this RFA will create high-resolution, high-content, multiscale biomarkers and maps of cellular senescence across the murine lifespan, to generate a murine-specific companion to the human Senescence atlas. The mouse component of the SenNet consortium will initially focus on healthy murine tissues (modified disease models are not allowed) derived from both inbred and outbred mouse strains that are commonly used and have demonstrated value in pre-clinical research. TMCs will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through analyses at organ-, tissue- and single-cell- level using omics, imaging and other approaches,
Wednesday, October 27, 2021 - 12:56am
Funding Opportunity RFA-HD-22-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants.
Wednesday, October 27, 2021 - 12:54am
Funding Opportunity RFA-AT-22-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for continuation of a Coordinating Center to provide national leadership for the NIH Health Care Systems (HCS) Research Collaboratory program. The Coordinating Center will 1) further develop, adapt, and adopt technical and policy guidelines and best practices for the effective conduct of research studies in partnership with health care systems; 2) work collaboratively with each Demonstration Project team supported through the Collaboratory program, including their partnering HCS, to develop, test, and implement the proposed Demonstration Projects while providing technical, design, and coordination support; 3) learn and disseminate the best strategies for engaging HCS as research partners to improve health and care delivery, with a particular focus on HCS with less historical involvement in research studies; and 4) learn, develop, and disseminate the best means of conducting pragmatic clinical trials in HCS to improve the scientific communitys ability to perform future pragmatic trials in a variety of healthcare contexts. The Coordinating Center will also serve as the central resource for the activities of the NIH HCS Research Collaboratory.
Tuesday, October 26, 2021 - 12:34am
Funding Opportunity RFA-HD-23-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications that address gaps in our understanding of best practices for promoting reproductive health across the transition from adolescence to adulthood for persons with disabilities, with the goal of producing an evidence base to improve care for these populations.
Tuesday, October 26, 2021 - 12:33am
Funding Opportunity RFA-AG-23-001 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support research studying the role of bilingualism as it relates to cognitive reserve/resilience in healthy aging and in Alzheimer's disease (AD) and Alzheimer's disease-related dementias(ADRD). This FOA aims to address the need for more prospective, hypothesis-driven research to build a theoretical framework and to clearly identify the extent to which acquiring a second language impacts human brain function. Multimodal and multidisciplinary studies are highly encouraged to improve our understanding of the complex interactions between neural, environmental, and sociocultural factors and the role of bilingualism in healthy aging and in AD/ADRD.
Tuesday, October 26, 2021 - 12:33am
Funding Opportunity RFA-CA-21-047 from the NIH Guide for Grants and Contracts. The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. Six-to-eight UG1 cooperative agreement mechanism-funded Clinical Sites, led by clinical investigators and/or clinicians, will provide a pluripotent clinical infrastructure to conduct/implement multiple prevention clinical trials through the CASCADE network and interface with network grantees during concept and protocol development to provide insights and input on clinical significance and study feasibility.
Tuesday, October 26, 2021 - 12:33am
Funding Opportunity RFA-CA-21-046 from the NIH Guide for Grants and Contracts. The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. Two-to-three cooperative agreement mechanism-funded Research Bases will be composed of a self-organized consortium of investigators with complementary expertise will provide scientific and statistical leadership for developing and analyzing multi-institutional clinical trial concepts and protocols to be implemented through this network, ensure regulatory and human subjects protection policy compliance, and work towards creating opportunities for training emerging investigators.
Tuesday, October 26, 2021 - 12:32am
Funding Opportunity RFA-CA-21-045 from the NIH Guide for Grants and Contracts. The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. The U24 cooperative agreement mechanism-funded Network Coordinating Center will coordinate all network activities, including concept and protocol review processes, provide centralized data management support, conduct independent clinical trials auditing for the network trials, and interface with network grantees for augmenting study training, reporting, and quality assurance activities.
Tuesday, October 26, 2021 - 12:24am
Notice NOT-AR-22-008 from the NIH Guide for Grants and Contracts
Tuesday, October 26, 2021 - 12:12am
Notice NOT-DE-21-017 from the NIH Guide for Grants and Contracts
Tuesday, October 26, 2021 - 12:07am
Notice NOT-HL-21-036 from the NIH Guide for Grants and Contracts

Pages